Atara Biotherapeutics Inc
NASDAQ:ATRA
Atara Biotherapeutics Inc
NASDAQ:ATRA
Price:
0.6036 USD
Market Closed
Updated:
May 17, 2024
Atara Biotherapeutics Inc
Long-Term Debt
|
Atara Biotherapeutics Inc
Long-Term Debt Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
Long-Term Debt
$35.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
182%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$52.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$60.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$376.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
18%
|
See Also
What is Atara Biotherapeutics Inc's Long-Term Debt?
Long-Term Debt
35.6m
USD
35.6m
USD
Based on the financial report for Mar 31, 2024, Atara Biotherapeutics Inc's Long-Term Debt amounts to 35.6m USD.
What is Atara Biotherapeutics Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
182%
182%
You don't have any saved screeners yet
